Article contents
Development of an EORTC Quality of Life Module for Renal Cell Cancer Patients: Phase I
Published online by Cambridge University Press: 01 September 2022
Abstract
In light of rising incidence rates and a mostly late diagnosis, renal cell cancer (RCC) patients are heavily burdened by both their disease and treatment. The structured assessment of their quality of life using patient-reported outcome (PRO) measures is important in order to provide them with appropriate interventions to maintain or improve their quality of life. Available questionnaires are predominantly symptom indices or were developed without conducting patient interviews.
Hence, we report on the ongoing phase I development of an EORTC module for RCC patients, which will be used together with the EORTC QLQ-C30 core questionnaire.
Following the EORTC Quality of Life Group’s Module Development Guidelines, a systematic literature review was conducted. Based on this review, issues were extracted and presented to healthcare professionals (HCPs) and patients for relevance assessment.
133 publications (14 on the development of RCC-specific PRO measures, 3 qualitative studies, 37 randomised controlled trials, 79 quantitative studies) were identified from which 150 unique issues were extracted. The issue list was reviewed by 14 HCPs (8 clinicians, 3 nurses, 2 psychooncologists, 1 physiotherapist) from 3 countries (Austria, Norway, United Kingdom) and rated regarding their relevance. An additional 13 issues were mentioned in the HCP interviews and included in the issue list.
The extended list of issues is currently used to interview patients. Data collection is expected to be completed by the conference, thus the poster will present the combined relevance scores (HCPs and patients) and the issues selected for the preliminary module to be tested in phase 3.
This study is funded by the EORTC Quality of Life Group (Grant 007/2019).
- Type
- Abstract
- Information
- European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S756
- Creative Commons
- This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Copyright
- © The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
- 1
- Cited by
Comments
No Comments have been published for this article.